Condition
Breast Cancer Nos Metastatic Recurrent
Total Trials
5
Recruiting
1
Active
1
Completed
3
Success Rate
75.0%-12% vs avg
Key Insights
Highlights
Success Rate
75% trial completion
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 37/100
Termination Rate
20.0%
1 terminated out of 5 trials
Success Rate
75.0%
-11.5% vs benchmark
Late-Stage Pipeline
20%
1 trials in Phase 3/4
Results Transparency
100%
3 of 3 completed with results
Key Signals
3 with results75% success
Data Visualizations
Phase Distribution
4Total
Not Applicable (1)
P 1 (1)
P 2 (1)
P 3 (1)
Trial Status
Completed3
Recruiting1
Terminated1
Trial Success Rate
75.0%
Benchmark: 86.5%
Based on 3 completed trials
Clinical Trials (5)
Showing 5 of 5 trials
NCT01703754Phase 2TerminatedPrimary
Adenoviral Vector Monotherapy or Combination With Chemotherapy in Subjects With Recurrent/Metastatic Breast Cancer.
NCT01993498Not ApplicableRecruitingPrimary
Chronic Toxicities Related to Treatment in Patients With Localized Cancer
NCT01554371Phase 1Completed
Eribulin in Combination With Cyclophosphamide in Patients With Solid Tumor Malignancies
NCT01644890Phase 3CompletedPrimary
A Phase III Study of NK105 in Patients With Breast Cancer
NCT01711502CompletedPrimary
Epidemiology and Management of Metastatic Breast Cancer
Showing all 5 trials